

June 12, 2017

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

Scrip code: 532531

The National Stock Exchange of India Limited

Exchange Plaza , Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051

Scrip code: STAR


Dear Sirs,

Sub: Press Release


Please find attached press release issued by the Company titled:

**“Strides Shasun receives USFDA Approval for
Amantadine Hydrochloride Tablets”**

Thanks & Regards,
For **STRIDES SHASUN LIMITED**



Manjula Ramamurthy
Company Secretary





Press Release

Monday, June 12, 2017

Strides Shasun Limited
(Formerly Strides Arcolab Limited)
Strides House, Bannerghatta Road,
Bangalore – 560076.

Strides Shasun receives USFDA Approval For Amantadine Hydrochloride Tablets

Bangalore, June 12, 2017 Strides Shasun today announced that it has received approval from the United States Food & Drug Administration (USFDA) for **Amantadine Hydrochloride Tablets 100 mg**. The product received approval in 15 months under the new GDUFA regime

According to IMS data, the US market for this product is approximately USD 22 Million with two generic players. The product will be launched immediately.

The Company also recently announced US FDA approval for Amantadine Hydrochloride Capsules and the combined market size of Tablets and Capsules is approximately USD 47 Million.


About Amantadine Hydrochloride Tablets

Amantadine Hydrochloride Tablets are indicated for the treatment of Parkinson's disease and in the treatment of Shingles (Herpes Zoster) to reduce pain.

About Strides Shasun Limited

Strides Shasun, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The Company has four business verticals, viz., Regulated Markets, Emerging Markets, Institutional Business and Active Pharmaceutical Ingredients.

The Company has global manufacturing foot print with 8 manufacturing facilities spread across three continents including 6 US FDA approved facilities and 8 facilities for the emerging markets. The Company has three dedicated R&D facilities in India with global filing capabilities and a strong commercial footprint across 85 countries. Additional information is available at the Company's website at www.stridesarco.com



For further information, please contact:

<u>Strides Shasun</u> Shashank Sinha, Managing Director +91 80 6784 0335 Vikesh Kumar +91 80 6784 0827 Kannan. N: +91 98450 54745 Sandeep Baid: +91 80 6784 0791	<u>PR Consultancy</u> Fortuna PR K Srinivas Reddy: +91 9000527213 srinivas@fortunapr.com K Priya: +91 9535425418 priya@fortunapr.com
--	--

